Full Press Release Details
Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH).
ALT
Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
Key Takeaway: Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
Price reaction · baseline $3.31 (2023-07-31 close) · hit after-hours · 1 other ALT headline(s) in the window, move may be shared
day 0 close · peak
-4.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight